[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"digestive-system-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:digestive-system-carcinoma":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":5},"100399013","cancer-genetic-testing-in-ethnic-populations-100399013",false,"NCT04475640","Cancer Genetic Testing in Ethnic Populations","GEMINI - Cancer Genetic Testing in Ethnic Populations","Inclusion Criteria:\n\n* Patients at least 18 years of age\n* Individuals diagnosed with any solid tumor cancer including, but not limited to, gastrointestinal, breast, gynecological, genitourinary, skin, central nervous system (CNS)\u002Fbrain, head\u002Fneck, musculoskeletal or cancer of unknown primary; and presenting to Mayo Clinic (MC Arizona or MC Florida) for clinical management\u002Ftreatment; and patients receive genetic testing as described above\n* Self-identified as being from various ethnic populations including Hispanic\u002FLatino, Native American\u002FAlaskan, African American (including of African descent), Asian and other European populations\n* Blood collection is feasible (health, access and\u002For tolerability) for requested blood sample(s)\n* Individuals have agreed to participate and signed the study informed consent form\n\nExclusion Criteria:\n\n* Patients who have had prior germline genetic testing involving a 40+ gene panel within the last 24 months at Mayo Clinic and available for review by the research coordinator at time of consent\n* Past or current history of hematological cancer (including leukemias, multiple myeloma)\n* All bone marrow transplants","ALL","18 Years",{"count":19,"type":20},1800,"ESTIMATED","INTERVENTIONAL",[23],"NA","This clinical trial examines the integration of cancer genetic testing in various ethnic populations. Studying individuals and families at risk of cancer may help identify cancer genes and other persons at risk. The information from this study may provide an opportunity for cancer risk stratification and individualized screening in these ethnic populations.",[26,27,28,29,30,31,32,33,34,35,36],"Breast Carcinoma","Carcinoma of Unknown Primary","Central Nervous System Carcinoma","Digestive System Carcinoma","Genitourinary System Carcinoma","Head and Neck Carcinoma","Malignant Brain Neoplasm","Malignant Female Reproductive System Neoplasm","Malignant Musculoskeletal Neoplasm","Malignant Solid Neoplasm","Skin Carcinoma","RECRUITING","2026-04-01",{"date":40,"type":41},"2026-04-02","ACTUAL",{"date":43,"type":41},"2020-01-13",{"date":45,"type":20},"2028-10-15",{"name":47,"class":48},"Mayo Clinic","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":76,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":91},"100571099","target-specific-immunopet-imaging-of-digestive-system-carcinoma-100571099","NCT06715839","Target-specific immunoPET Imaging of Digestive System Carcinoma","Development and Clinical Translation of immunoPET Imaging Probes for Digestive System Carcinoma","Inclusion Criteria:\n\n1. Aged 18-75 years old and of either sex；\n2. Histologically confirmed diagnosis of digestive system carcinoma or suspected digestive system carcinoma by diagnostic imaging;\n3. Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n1. Pregnancy；\n2. Severe hepatic and renal insufficiency;\n3. History of serious surgery in the last month;\n4. Allergic to antibody or single-domain antibody radiopharmaceuticals.","75 Years",{"count":58,"type":20},400,[23],"The aim of this study is to establish and optimize the target-specific PET\u002FCT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in digestive system malignant tumors will be evaluated.",[62,63,64,29,65,66,67,68,69,70,71,72,73,74,75],"Malignancy","Digestive Cancer","Digestive System Neoplasm","Digestive System Cancer","Liver Cancer","Stomach Cancer","Colon Cancer","Rectum Cancer","Pancreatic Cancer","Esophagus Cancer","Gallbladder Carcinoma","Small Intestine Cancer","Appendix Cancer","Bile Duct Carcinoma",[77,78,79,80,81],"human epidermal growth factor receptor 2 (HER2)","Trophoblast cell surface antigen 2 (TROP2)","Glypican-3 (GPC3)","Glycoprotein A33 (gpA33)","Nectin cell adhesion molecule-4 (Nectin-4)","2025-12-25",{"date":84,"type":41},"2025-12-31",{"date":86,"type":41},"2024-12-04",{"date":88,"type":20},"2027-09",{"name":90,"class":48},"RenJi Hospital",1]